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Abstract
Purpose To explore the preoperative utility of FDG PET for
the diagnosis and prognosis in a retrospective breast cancer
case series.
Methods In this retrospective study, 104 patients who had
undergone a preoperative FDG PET scan for primary breast
cancer at the UZ Brussel during the period 2002–2008 were
identified. Selection criteria were: histological confirmation,
FDG PET performed prior to therapy, and breast surgery
integrated into the primary therapy plan. Patterns of increased
metabolism were recorded according to the involved loca-
tions: breast, ipsilateral axillary region, internal mammary
chain, or distant organs. The end-point for the survival anal-
ysis using Cox proportional hazards was disease-free survival.
The contribution of prognostic factors was evaluated using the
Akaike information criterion and the Nagelkerke index.
Results PET positivity was associated with age, gender, tu-
mour location, tumour size >2 cm, lymphovascular invasion,
oestrogen and progesterone receptor status. Among 63 patients
with a negative axillary PET status, 56 (88.9 %) had three or
fewer involved nodes, whereas among 41 patients with a pos-
itive axillary PET status, 25 (61.0 %) had more than three
positive nodes (P<0.0001). In the survival analysis of preoper-
ative characteristics, PET axillary node positivity was the fore-
most statistically significant factor associated with decreased
disease-free survival (hazard ratio 2.81, 95% CI 1.17–6.74).
Conclusion Preoperative PET axillary node positivity iden-
tified patients with a higher burden of nodal involvement,
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which might be important for treatment decisions in breast
cancer patients.
Keywords Breast cancer . Prognosis . Survival . Lymph
nodes . Staging . Surgery
Introduction
The diagnostic value, i.e. the ability to detect disease, of
FDG PET in breast cancer have been investigated in many
studies. The consensus from several reviews is that due to its
limited spatial resolution PET lacks sensitivity for the diag-
nostic assessment of the axilla in patients with early breast
cancer [1–5]. Most guidelines tend to recommend PET for
breast cancer only in particular circumstances (in advanced
disease, for recurrences, for treatment monitoring and possibly
to evaluate the efficacy of neoadjuvant therapy) [6–12]. The
prognostic value of FDG PET in breast cancer has received
considerably less attention [13–16].
At the UZ Brussel, starting informally at the end of 2002,
patients with operable breast cancer referred for primary
treatment have received a whole-body FDG PET scan pre-
operatively, depending on appointment availability. The ra-
tionale was to use the scan for staging, and to improve target
delineation for subsequent postoperative radiation treatment
[17]. In the present study, we evaluated the diagnostic utility
of the preoperative PET scan with regard to lymph node
involvement, and also evaluated its prognostic value with
regard to survival.
Materials and methods
We retrospectively identified patients presenting with pri-
mary breast cancer who received a PET scan at the UZ
Brussel between 2002 and 2008. The study was approved
by the institution’s review committee. We selected patients
in whom the cancer was the first primary breast cancer and
in whom surgery was part of planned primary therapy.
Patients with sarcoma of the breast, surgery performed but
not as part of primary therapy, no histopathological confirma-
tion of cancer, noninvasive carcinoma, or clinical metastatic
disease were excluded.
FDG PET image acquisition and reconstruction
The procedure at the UZ Brussel has been previously
reported [17]. The patients fasted for at least 6 h. Prescan-
ning glucose levels were systematically checked. Tracer
activity administered ranged from 370 to 536 MBq (average
464±56 MBq). Imaging was performed with the patients in
the supine position with the arms placed above the head.
Whole-body images corrected for attenuation were acquired
with an LSO PET camera (ECAT Accel; Siemens, Hoffman
Estates, IL) 60 min after tracer administration according to
an interleaved protocol. Emission data were obtained in
three-dimensional mode over 3 min per bed position. For
transmission, 68Ge sources (3×74 MBq; decay-corrected)
were used and data were acquired in two-dimensional mode
over 2 min per bed position. Emission data were recon-
structed iteratively (OSEM, two iterations, 16 subsets), cor-
rected for scatter, and a postreconstruction filter (6 mmGauss)
was applied. Filtered back-projection was used for the trans-
mission. The constructed attenuation map was subsequently
segmented into regions with similar attenuation factors. This
segmented image was then forward-projected to obtain atten-
uation correction factors for each line of response. Only PET
scanning was used.
Data abstraction
Data were retrieved from the patients’ medical records,
which included the FDG PET diagnostic summary report
and a single-page hard-copy print-out of images. Standard-
ized uptake values (SUV) were not routinely recorded. Due
to changes in the archiving system over time, full PET
imaging and SUV could not be consistently retrieved. Pat-
terns of PET positivity were abstracted from the diagnostic
reports according to the absence or presence of increased
metabolic uptake in the following sites: involved breast,
ipsilateral axillary region, internal mammary chain, or dis-
tant organs. Diagnosis of increased uptake was based on
visual inspection globally, right versus left comparison, and
tracer distribution within areas of interest (breast right and
left, axillary right and left, peristernal, and elsewhere)
(Fig. 1). We used the first examination in patients who had
received a repeat PET scan. In patients with bilateral syn-
chronous breast tumours, we retained the side of the first
histopathological confirmation if there were different histo-
pathology dates, or the side which had more axillary lymph
nodes removed.
Survival times were computed from the date of first
pathological diagnosis to the date of last known follow-up
status. Events for evaluating disease-free survival (DFS)
were defined as local-regional or distant recurrence, second-
ary tumour, or death from any cause. Recurrence and meta-
static disease status were based on assessment of the
physicians in charge of the patient as recorded in the
medical files.
Statistical data analysis
Missing data The diagnostic procedure for first histopathol-
ogy was missing in one patient, HER2-neu score in one
patient, oestrogen receptor (ER) and progesterone receptor
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(PR) status in one patient, grade in four patients, tu-
mour size in one patient, and number of examined and
positive nodes in five patients (Table 1). These were
imputed using the method of multivariate imputation by
chained equations [18]. Assessment of presence or ab-
sence of lymphovascular invasion was missing in 20
patients. We did not impute the missing lymphovascular
invasion, but classified it as yes, no or unknown. HER2
fluorescence in situ hybridization (FISH) data were missing
in 51 patients, and we did not use data from this test in the
analyses.
Analysis procedures For descriptive purposes, we used a
contingency table to summarize the patient characteristics,
complemented by step-wise logistic regression to identify
the more significant relationships between PET positivity
and patient age at diagnosis, gender, source of first pathol-
ogy, histology, grade, neu status, lymphovascular invasion,
hormone receptor status, T4 stage, laterality, tumour
location, and tumour size. Nodal involvement assessed post-
operatively was separately detailed according to PET posi-
tivity. For survival analyses, the end-point was DFS, where
an event was defined as any local-regional or distant recur-
rence, new primary tumour, or death from any cause. The
Kaplan-Meier method was used for univariate analysis of
survival [19]. Cox proportional hazards models were used
for multivariate analysis of survival [20]. The variables
considered for inclusion in the Cox models by step-wise
regression were patient age at diagnosis, gender, source of
first pathology, histology, grade, neu status, lymphovascular
invasion, hormone receptor status, T4 stage, laterality, tu-
mour location, tumour size, PET characteristics, nodal var-
iables, number of positive nodes, number of examined
nodes, and lymph node ratio (LNR, number of positive/
number of examined nodes) [21], neoadjuvant therapy, type
of surgery, adjuvant chemotherapy, adjuvant hormone ther-
apy, and adjuvant radiation therapy. The Akaike information
criterion (AIC) was used for the step-wise selection of
variables. The AIC does not rely on P values. The AIC
penalizes a model’s log likelihood against the number of
parameters brought into the models by a variable. A variable
is considered informative if it reduces the AIC. Nagelkerke’s
index (R2N) was used to evaluate the relative importance of
the variables selected. The Nagelkerke R2N index repre-
sents the proportion of variation explained by covariates in a
regression model. R2N ranges from 0 to 1; it is close to 1 for
a perfectly predictive model, and close to 0 for a model that
has no predictive value.
R version 2.10.1 was used for all statistical computations.
The package MICE was used for imputation of missing data
[18]. The generalized linear model from the Stats package was
used for logistic regression. The stepAIC function from the
MASS package was used for step-wise selection of variables
for the logistic regression and the Cox models [22].
Results
Out of 157 consecutive records, there were 104 patients
matching the selection criteria, who constituted the study
population. Causes of exclusion were: PET after surgery (17
patients), breast surgery was not first intention (12 patients),
previous primary cancer (8 patients), duplicated records
(5 records), no cancer (2 patients), no axillary exploration
(2 patients), missing histological data (2 patients), sarcoma
(2 patients), unknown primary therapy (2 patients), ductal
carcinoma in situ (1 patient). Of the 104 patients, 85
(81.7%) received immediate surgery, and 19 (18.3%) re-
ceived surgery after neoadjuvant therapy. Surgical nodal
exploration was limited to the axilla; internal mammary
chain nodes were not dissected. The median overall
follow-up time in the 104 patients was 59 months (inter-
quartile range 39–64 months). Other patient characteristics
are summarized in Table 1.
The more significant patient characteristics associated
with different PET positivity according to models selected
by AIC are summarized in Table 2. An increased odds ratio
for PET positivity in the primary breast tumour was associ-
ated with male gender, ductal histology, and larger tumour
size. An increased odds ratio for nodal positivity was asso-
ciated with young age, presence of lymphovascular inva-
sion, and negative oestrogen and/or negative progesterone
receptor. Large tumour size was not significant (odds ratio
1.14, 95% CI 0.96–1.36), but it was retained by the AIC
selection as a risk factor for nodal positivity. Increased risk
of PET positivity in the internal mammary chain or in
distant sites was associated with bilateral tumours, clinical
PET imaging hard copy of screen. Patient scored as PetT+ and PetN+. 
Fig. 1 PET imaging hard-copy of screen. Patient scored as PetT+
and PetN+
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Table 1 Patient characteristics according to PET pattern. Characteristics significantly associated with PET positivity are highlighted in bold type
(compare Table 2)
Characteristic All patients
(n 0104)
PET positivity
Breast
(n 087)
Axillary/supraclavicular
region (n 041)
Internal mammary
chain (n 06)
Distant organs
(n 018)
No. of
patients
Unadjusted
relative risk
No. of
patients
Unadjusted
relative risk
No. of
patients
Unadjusted
relative risk
No. of
patients
Unadjusted
relative risk
Age at diagnosis (years)
<40 6 6 1.20 6 2.54 0 0.00 0 0.00
40-59 49 42 1.02 15 0.78 1 0.35 7 0.83
≥60 49 39 0.95 20 1.04 5 1.77 11 1.30
Male gender 2 2 1.20 0 0.00 0 0.00 0 0.00
Source of first pathology
Fine needle aspiration 52 46 1.06 21 1.02 5 1.67 9 1.00
Trucut/Mammotome biopsy 34 27 0.95 10 0.75 0 0.00 6 1.02
Surgical procedure 12 9 0.90 5 1.06 1 1.44 2 0.96
Non-breast site 5 4 0.96 4 2.03 0 0.00 1 1.16
Unknown 1 1 1.20 1 2.54 0 0.00 0 0.00
Clinical T4 stage 8 7 1.05 4 1.27 2 4.33 3 2.17
Tumour laterality
Bilateral 5 5 1.2 4 2.03 2 6.93 3 3.47
Left 46 38 0.99 17 0.94 4 1.51 11 1.38
Right 53 44 0.99 20 0.96 0 0 4 0.44
Tumour quadrant
Inner 17 14 0.98 5 0.75 1 1.02 5 1.70
Central 14 13 1.11 4 0.72 0 0.00 2 0.83
Outer 68 55 0.97 29 1.08 3 0.76 9 0.76
Other 4 4 1.20 2 1.27 2 8.67 1 1.44
Unknown 1 1 1.20 1 2.54 0 0.00 1 5.78
Primary systemic therapy 19 15 0.94 11 1.47 2 1.82 4 1.22
Surgery
Mastectomy 77 71 1.10 35 1.15 6 1.35 17 1.28
Tumorectomya 27 16 0.71 6 0.56 0 0.00 1 0.21
Radiation therapy
None 9 8 1.06 4 1.13 0 0.00 2 1.28
Postoperative 92 76 0.99 36 0.99 6 1.13 15 0.94
Preoperative 2 2 1.20 1 1.27 0 0.00 0 0.00
Radiosurgery 1 1 1.20 0 0.00 0 0.00 1 5.78
Postop chemotherapy 53 48 1.08 30 1.44 2 0.65 7 0.76
Anthracycline 36 32 1.06 21 1.48 1 0.48 5 0.80
Taxane 11 9 0.98 7 1.61 0 0.00 1 0.53
Postoperative hormone therapyb 88 75 1.02 32 0.92 5 0.98 16 1.05
Grade
1 29 26 1.07 8 0.70 1 0.60 4 0.80
2 42 34 0.97 15 0.91 2 0.83 10 1.38
3 29 25 1.03 17 1.49 2 1.20 4 0.80
Unknown 4 2 0.60 1 0.63 1 4.33 0 0.00
Lymphovascular invasion
Yes 39 37 1.13 27 1.76 3 1.33 8 1.19
No 45 35 0.93 8 0.45 2 0.77 6 0.77
Unknown 20 15 0.90 6 0.76 1 0.87 4 1.16
Histology
Invasive ductal carcinoma 84 75 1.07 36 1.09 4 0.83 16 1.10
Lobular carcinoma 14 8 0.68 3 0.54 2 2.48 1 0.41
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T4 stage, and inner, medial or overlapping quadrants. Age
60 years or older was also associated with a significantly
increased risk of PET positivity in the internal mammary
chain or at distant sites, with relative risks of, respectively,
1.77 and 1.30 (Table 1). Although age 60 years or more is not
retained in Table 2, when the analyses were run pooling the
combined risk of internal mammary chain and distant site
positivity, age 60 years or more was retained by the AIC,
giving an odds ratio of 1.14 (95% CI 0.99–1.32, P00.07).
Regarding the postoperative nodal information, among
the PET node-positive patients, 35 were histopathological
node-positive (Table 1; 1–3 positive nodes in 11 patients, 4–
Table 1 (continued)
Characteristic All patients
(n 0104)
PET positivity
Breast
(n 087)
Axillary/supraclavicular
region (n 041)
Internal mammary
chain (n 06)
Distant organs
(n 018)
No. of
patients
Unadjusted
relative risk
No. of
patients
Unadjusted
relative risk
No. of
patients
Unadjusted
relative risk
No. of
patients
Unadjusted
relative risk
Otherc 6 4 0.80 2 0.85 0 0.00 1 0.96
Hormone receptor status
ER+/PR+ 67 54 0.96 16 0.61 2 0.52 10 0.86
ER−/PR– 20 17 1.02 14 1.78 2 1.73 5 1.44
Other 17 16 1.13 11 1.64 2 2.04 3 1.02
Neu status
0/1 56 45 0.96 19 0.86 5 1.55 10 1.03
2/3 47 41 1.04 21 1.13 1 0.37 8 0.98
Unknown 1 1 1.20 1 2.54 0 0.00 0 0.00
HER-2 FISH ratio
<2 42 35 1.00 17 1.03 2 0.83 9 1.24
≥2 11 11 1.20 6 1.38 0 0.00 1 0.53
Unknown 51 41 0.96 18 0.90 4 1.36 8 0.91
Tumour size (mm)
0–20 37 25 0.81 8 0.55 2 0.94 5 0.78
>20 66 61 1.10 32 1.23 4 1.05 13 1.14
Unknown 1 1 1.20 1 2.54 0 0.00 0 0.00
Number of positive nodes
0 39 29 0.89 5 0.33 2 0.89 4 0.59
1–3 30 28 1.12 11 0.93 0 0.00 7 1.35
4–9 20 18 1.08 14 1.78 1 0.87 2 0.58
≥10 10 9 1.08 10 2.54 2 3.47 4 2.31
Unknown 5 3 0.72 1 0.51 1 3.47 1 1.16
Number of examined nodes
0 5 3 0.72 1 0.51 1 3.47 1 1.16
1–9 25 17 0.81 1 0.10 2 1.39 4 0.92
≥10 74 67 1.08 39 1.34 3 0.70 13 1.02
Lymph node ratio
0 39 29 0.89 5 0.33 2 0.89 4 0.59
0.01–0.20 30 28 1.12 12 1.01 0 0.00 7 1.35
0.21–0.65 18 16 1.06 12 1.69 1 0.96 1 0.32
0.66–1.00 12 11 1.10 11 2.33 2 2.89 5 2.41
Unknown 5 3 0.72 1 0.51 1 3.47 1 1.16
Events
Local-regional recurrence 1 1 1.20 0 0.00 0 0.00 0 0.00
Distant metastases 20 17 1.02 13 1.65 3 2.60 5 1.44
Death from any cause 10 7 0.84 6 1.52 1 1.73 3 1.73
a One case of radiosurgery assimilated with tumorectomy.
b Includes one unknown.
c One mixed ductal lobular, one invasive papillary, one medullary, one tubular, one unspecified, one undifferentiated.
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9 in 14, and 10+ in 10), and in 34 of these patients the
pathological record mentioned coloration. Node positivity
was based on haematoxylin-eosin (HE) staining of >2 mm
in all these 34 patients (100%). Among the PET node-negative
patients, 25 were histopathological node-positive, and in 24 of
these patients the record mentioned coloration: node positivity
in 15 patients was based onHE staining of >2mm, in 4HE >0.2
and ≤2mm, in 1 small HE clusters, and in 4 immunohistochem-
ical only, that is minimal involvement in 37.5%. Extracapsular
extension was noted in 9 of 30 PET node-positive patients
(30%) for whom extracapsular information was available, as
compared with 3 of 21 PET node-negative patients (14%).
Quantitative nodal information is summarized in Table 1,
while more detailed information including imputed cases is
provided in Table 3, with the corresponding graphical display
in Fig. 2. Among 63 PET node-negative patients, 26 (41.3%)
were histopathological node-positive. Among 41 PET node-
positive patients, 36 (87.8%) were histopathological node-
positive (Table 3). Taking into consideration the TNM classi-
fication of lymph node involvement in which three or fewer
involved nodes is stage pN0/1 and more than three involved
nodes is stage pN2/3 [23], among the PET node-negative
patients, 56 (88.9%) were pN0/1 and 7 (11.1%) were pN2/3,
whereas among the PET node-positive patients, 16 (39.0%)
were pN0/1 and 25 (61.0%) were pN2/3 (P<0.0001, chi-
squared test). Taking into consideration the Geneva classifi-
cation in which LNR ≤0.20 is low risk and LNR >0.20 is
intermediate/high risk [24], among the PET node-negative
patients, 55 (87.3%) were low risk LNR and 12.7% were
intermediate/high risk LNR, whereas among PET node-
positive patients, 17 (41.5%) were low risk LNR and 24
(58.5%) were intermediate/high risk LNR (P<0.0001).
Analysis of unadjusted survival showed significantly dif-
ferent DFS according to PET axillary nodal status (P00.017)
with a 3-year DFS of 89% (95% CI 81–97%) in PET node-
negative patients and 68% (95% CI 55–85%) in PET node-
positive patients (Fig. 3). The difference was more significant
when PET axillary status was combined with internal mam-
mary status (P00.013; not shown). No significant survival
differences were found analysing PET breast, internal mam-
mary, or distant status separately.
We ran two separate multivariate survival analyses, one
including all variables except number of positive nodes, num-
ber of examined nodes, and LNR, and the other including
number of positive nodes, number of examined nodes, and
LNR. In the first run, step-wise regression with AIC retained
only three variables: PET axillary status, age, and adjuvant
hormone therapy. The corresponding hazard ratios are shown
in Table 4. In the second run, the regression retained only the
LNR, adjuvant hormone therapy, and adjuvant chemotherapy,
the corresponding hazard ratios are shown in Table 4. As
shown in Table 4. PET nodal status was considerably super-
seded by LNR, i.e. LNR gave a larger AIC reduction and
increased R2N. However, in the absence of LNR information,
PET nodal status was the foremost prognostic factor with a
hazard ratio for DFS of 2.81 (95% CI 1.17–6.74) (Table 4).
Note that adjuvant chemotherapy alone did not improve mod-
el information (negative AIC), but was nevertheless retained
when the model included LNR.
Discussion
PET axillary nodal status was found to be the foremost
preoperative prognostic factor for DFS in our patients. This
is in line with the relationship between PET positivity and
adverse prognostic factors such as tumour size, axillary
lymph node status, histological type, histological grade,
Table 2 Preoperative variables associated with PET positivity selected by step-wise logistic regression. The values are odds ratio (95% CI)
Variable PET positivity
Breast Axillary/supraclavicular
region
Internal
mammary chain
Distant organs
Age <40 vs. ≥40 years – 1.46 (1.04–2.05) – –
Age ≥60 vs. <60 0.88 (0.77–1.00) – – –
Male vs. female 1.46 (0.91–2.36) – – –
Bilateral breast tumours vs. unilateral – – 1.40 (1.15–1.70) 1.60 (1.15–2.22)
Quadrant inner, central, overlapping vs. outer – – – 1.14 (0.98–1.32)
Tumour size >2 cm vs. ≤2 cm 1.35 (1.17–1.55) 1.14 (0.96–1.36) – –
T4 stage vs. not T4 stage – – 1.20 (1.02–1.40) –
Ductal histology vs. nonductal or mixed ductal 1.38 (1.17–1.62) – – –
Lymphovascular invasion vs. no – 1.40 (1.18–1.66) – –
ER–/PR– vs. ER+/PR+ – 1.44 (1.18–1.76) – –
ER+/PR– or ER–/PR+ vs. ER+/PR+ – 1.26 (1.01–1.58) – –
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and hormone receptor status [25–31]. Oshida et al. reported
overall and relapse-free survival in 70 patients according to
differential absorption ratio [13].Mankoff et al. found in a series
of 37 patients a poorer DFS among those who presented with a
high tumour metabolic rate as shown by high FDG uptake [14].
Inoue et al. in a case series of 81 patients with preoperative PET
found that patients with a high SUV (SUVmax) and positive
PET nodal status showed a significantly poorer prognosis than
the other patients with 5-year DFS of 44.4% vs. 96.8% [15].
Jung et al. reported the prognostic impact of PET response after
neoadjuvant therapy, but did not assess the relationship between
baseline PET status and survival [32]. Ueda et al. reported
higher relapse and mortality rate associated with high SUV,
but they did not report survival data [26].
Regarding the study’s objective of evaluating the diagnos-
tic utility of preoperative PET, it might be noted that among 63
PET node-negative patients, 26 had lymph node involvement,
i.e. missed by PET (sensitivity). This confirms the low sensi-
tivity of PET for detecting nodal involvement, as already
reported in the literature. Positive PET axillary nodal status
was associated with the extent of nodal involvement. In PET
node-negative patients, the risk of major nodal involvement
decreased considerably (Fig. 2), whereas in patients PET
node-positive patients, the risk was particularly high (Fig. 2).
The probability estimates suggest that in sentinel node-
positive but preoperative PET node-negative patients, the risk
of additional positive nodes is small, and there would be no
Table 3 Relationship between
histopathological nodal involve-
ment and PET nodal positivity
in the axillary-supraclavicular
region. Figures are number of
patients, using imputation
for five missing patients
Number of positive
lymph nodes
PET nodal status Lymph node ratio Histopathological
nodal status
Negative
(n063)
Positive
(n041)
Negative
(n063)
Positive
(n041)
0 37 5 0 37 5
1 11 4 0.01–0.10 11 7
2 5 5 0.11–0.20 7 5
3 3 2 0.21–0.30 2 7
4 1 4 0.31–0.40 3 4
5 3 3 0.41–0.50 0 2
6 1 2 0.51–0.60 1 0
7 2 1 0.61–0.70 1 3
8 0 1 0.71–0.80 0 3
9 0 4 0.81–0.90 0 3
10+ 0 10 0.91–1.00 1 2
Probabilities of nodal involvement according to PET nodal status.
Fig. 2 Probabilities of nodal involvement according to PET nodal
status
Disease free survival according to PET axillary nodal status 
Fig. 3 Disease-free survival according to PET axillary nodal status
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need to proceed to complete axillary lymph node dissection.
In sentinel node-positive and preoperative PET node-positive
patients, the risk of additional positive nodes is high, which
could justify complete axillary dissection or radiation therapy
of the regional lymph node. From a diagnostic perspective, if
the purpose is to classify lymph node involved versus not
involved, then preoperative PET is not efficient. However, if
the purpose is to classify low versus high burden of lymph
node involvement, then preoperative PET may represent a
powerful tool for stratification. Prospective studies might be
warranted to evaluate how PET information can be combined
with nomograms for the prediction of non-sentinel node
involvement.
Other noteworthy observations were the association of age
<40 years with PET node positivity, whereas age >60 years
was marginally associated with PET-positive internal mam-
mary chain and distant organs. Bilateral breast cancer was
associated with PET-positive internal mammary chain and
distant organs. Lymphovascular invasion was found signifi-
cantly associated with PETaxillary node positivity, in keeping
with the findings ofMankoff et al. who reported the predictive
ability of metabolic FDG uptake and blood flow in patients
with locally advanced breast cancer [14], and Groves et al.
who reported that FDG uptake was highly significantly asso-
ciated with angiogenesis [28]. Tumour size, ER/PR status and
ductal histology were also in keeping with the findings of
other correlation studies [25, 27].We have previously reported
the poorer prognosis associated with breast inner quadrant
location [33]. The present study found a trend for a higher
risk of PET-positive distant organs associated with medial/
central tumour location. Male gender appeared to be associ-
ated with increased risk of breast PET positivity. We are not
aware of previous reports of this finding. However, although
we had only two male patients with breast cancer, the odds
ratio of 1.48 retained by AIC selection was nevertheless not
significant (95% CI 0.93–2.36; Table 2).
We acknowledge several limitations. The study was retro-
spective, implying selection bias, most patients receiving pre-
operative PET were more likely to have more advanced
disease than a population of screened patients. Only 39
(37.5%) of the 104 patients were node-negative. Our data also
included eight patients with T4 stage. We used pathological
tumour size, which can be affected by neoadjuvant therapy.
The number of events was small, which limits the number of
variables that could be found significant, and did not allow
detailed subgroup analyses. We did not formally investigate
how different cut-offs of tumour size could affect PET posi-
tivity. We used multiple outcomes and multiple testings in our
analyses. Metastatic status was attributed with knowledge of
the PET findings, and furthermore surgery included patients
with metastatic disease, which could have biased the results.
There were missing data that required imputation, which can
limit the reliability of results. SUVmax has been shown to be a
prognostic factor for survival of those with operable breast
cancer [15], as well as of those with metastatic breast cancer
[34]. Our scoring of PET positivity was based on visual
inspection, making it liable to observer variability. SUVmeas-
urements were not used. Due to changes in image archiving
systems, we were only able to retrieve the records of 51
patients in whom SUVmax could be estimated (Appendix).
This number of patients was too small to efficiently evaluate
the contribution of SUVmax in our patient’s population.
Despite these limitations, we believe that the study pro-
vides data that warrants further investigations. The data di-
rectly reflect the daily practice and the clinical status of the
patients. PET-positive distant organs could have affected the
staging; however, all our selected patients received surgery as
planned by first intent. The number of patients (104) was
insufficient for subgroup analyses, yet that number is a non-
negligible contribution to evaluate the role of preoperative
PET. In version 1.2011 of the clinical practice guidelines in
oncology for breast cancer of the National Comprehensive
Cancer Network, the recommendations discourage the use of
PET or PET/CT in the staging of clinical stage I, stage II, or
operable stage III breast cancer [12]. Our results present a
counterpoint. Postoperatively, lymph node involvement was
confirmed as the most important prognostic factor. Based on
values of the R2N index, the histopathological lymph node
Table 4 Multivariate analysis of DFS based on step-wise selection. A hazard ratio for DFS of <1 indicates improvedDFS, and >1 indicates poorer DFS.
AIC and R2N were computed relative to a model without variables
Variable Model with PET
nodal status
Model with LNR Model scoring
Hazard
ratios
95% CI Hazard
ratios
95% CI AIC
reduction
R2N
contribution
Axillary PET-positivity (vs. axillary PET-negative) 2.81 1.17–6.74 – – 3.35 0.059
Age (continuous, years) 1.05 1.01–1.09 – – 2.15 0.046
Adjuvant hormone therapy (vs. no adjuvant hormone therapy) 0.43 0.16–1.13 0.28 0.10–0.77 0.70 0.030
Adjuvant chemotherapy (vs. no adjuvant chemotherapy) – – 0.46 0.19–1.12 −1.93 0.000
Lymph node ratio – – 24.82 7.14–86.3 19.16 0.217
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ratio provided prognostic information that was a 3.7 times
stronger predictor of survival than the PET status (0.217/
0.059, Table 4). However, preoperatively—which matters
when treatment options are under consideration in newly
diagnosed patients—out of 12 conventional preoperative
prognostic factors (as listed in Materials and methods), PET
was the only unequivocal preoperative predictor of DFS,
overriding all other factors (Table 4). Recently there has been
a growing trend for not dissecting the axillary lymph nodes
even in patients with a positive sentinel node [35]. Even
though this might be considered safe, the trend implies that
prognostic information becomes poorer. Considering that pre-
operative PET provided prognostic information second only
to postoperative lymph node extent of involvement, outright
rejection of preoperative PET at a time when axillary dissec-
tion is no longer performed further deprives patients of the
next most important prognostic tool. This is an issue that may
become critically important in view of a recent randomized
trial showing a poorer survival in women who did not undergo
axillary clearance [36].
We are currently conducting a prospective trial of preoper-
ative FDG PET/CT recruiting patients with T1/2 node-
negative breast cancer (ClinicalTrials.gov, NCT01432002)
[37]. We hope that the trial will provide further data to eval-
uate the hypothesis that preoperative PET might stratify
patients into different risk groups.
Conclusion
Positive axillary PET in the preoperative assessment of breast
cancer patients was significantly associated with a poorer
DFS, and was predictive of a high metastatic lymph node
involvement. We argue that the role of preoperative PET as a
surrogate indicator of lymph node involvement and as a
marker of survival should be taken into consideration as a
potential tool for treatment decision.
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